Condition: Colon Adenocarcinoma · Sponsor: Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
This multicenter, randomized, open-label, blinded-endpoint Phase II trial assesses the efficacy and safety of tolecizumab (PCSK9 inhibitor) plus sintilimab/CapeOX chemoimmunotherapy as neoadjuvant treatment for pMMR/MSS locally advanced colon adenocarcinoma (cT3c+). 106 patients are 1:1 randomized to the combination or chemoimmunotherapy alone, with pCR as the primary endpoint.
This description comes directly from the study's public registry record.
fan Li, PhD · 86-18696539200 · levinecq@163.com
Always discuss trial participation with your own doctor first.
| Daping Hospital Third Military Medical University, chongqing, chongqing 400000 Recruiting | Chongqing, Chongqing Municipality, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07468630